261 related articles for article (PubMed ID: 28126301)
1. Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer.
Shaverdian N; Verruttipong D; Wang PC; Kishan AU; Demanes DJ; McCloskey S; Kupelian P; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):516-525. PubMed ID: 28126301
[TBL] [Abstract][Full Text] [Related]
2. Impact of the Primary Information Source Used for Decision Making on Treatment Perceptions and Regret in Prostate Cancer.
Shaverdian N; Kishan AU; Veruttipong D; Demanes DJ; Kupelian P; McCloskey S; Steinberg ML; King CR
Am J Clin Oncol; 2018 Sep; 41(9):898-904. PubMed ID: 28537990
[TBL] [Abstract][Full Text] [Related]
3. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.
Kishan AU; Wang PC; Upadhyaya SK; Hauswald H; Demanes DJ; Nickols NG; Kamrava M; Sadeghi A; Kupelian PA; Steinberg ML; Prionas ND; Buyyounouski MK; King CR
Pract Radiat Oncol; 2016; 6(4):268-275. PubMed ID: 26850649
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.
Evans JR; Zhao S; Daignault S; Sanda MG; Michalski J; Sandler HM; Kuban DA; Ciezki J; Kaplan ID; Zietman AL; Hembroff L; Feng FY; Suy S; Skolarus TA; McLaughlin PW; Wei JT; Dunn RL; Finkelstein SE; Mantz CA; Collins SP; Hamstra DA;
Radiother Oncol; 2015 Aug; 116(2):179-84. PubMed ID: 26276528
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
[TBL] [Abstract][Full Text] [Related]
6. Long-term decision regret after post-prostatectomy image-guided intensity-modulated radiotherapy.
Shakespeare TP; Chin S; Manuel L; Wen S; Hoffman M; Wilcox SW; Aherne NJ
J Med Imaging Radiat Oncol; 2017 Feb; 61(1):141-145. PubMed ID: 27531363
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported Quality of Life After SBRT, LDR, and HDR Brachytherapy for Prostate Cancer: A Comparison of Outcomes.
Paly JJ; Egleston BL; Wong JK; Burbure N; Sobczak ML; Hayes SB; Chen DYT; Horwitz EM; Hallman MA
Am J Clin Oncol; 2021 Apr; 44(4):131-136. PubMed ID: 33577175
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
[TBL] [Abstract][Full Text] [Related]
9. An age-corrected matched-pair study of erectile function in patients treated with dose-escalated adaptive image-guided intensity-modulated radiation therapy vs. high-dose-rate brachytherapy for prostate cancer.
Marina O; Warner J; Ye H; Grills IS; Shah C; Wallace M; Gustafson GS; Brabbins DS; Martinez AA; Krauss DJ
Brachytherapy; 2014; 13(2):163-8. PubMed ID: 24295963
[TBL] [Abstract][Full Text] [Related]
10. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
Halpern JA; Sedrakyan A; Hsu WC; Mao J; Daskivich TJ; Nguyen PL; Golden EB; Kang J; Hu JC
Cancer; 2016 Aug; 122(16):2496-504. PubMed ID: 27224858
[TBL] [Abstract][Full Text] [Related]
11. Decision regret in men undergoing dose-escalated radiation therapy for prostate cancer.
Steer AN; Aherne NJ; Gorzynska K; Hoffman M; Last A; Hill J; Shakespeare TP
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):716-20. PubMed ID: 23608238
[TBL] [Abstract][Full Text] [Related]
12. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
Nakamura S; Murakami N; Inaba K; Wakita A; Kobayashi K; Takahashi K; Okamoto H; Umezawa R; Morota M; Sumi M; Igaki H; Ito Y; Itami J
BMC Cancer; 2016 May; 16():296. PubMed ID: 27142069
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
[TBL] [Abstract][Full Text] [Related]
14. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
[TBL] [Abstract][Full Text] [Related]
15. A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy.
Hegde JV; Collins SP; Fuller DB; King CR; Demanes DJ; Wang PC; Kupelian PA; Steinberg ML; Kamrava M
Am J Clin Oncol; 2018 May; 41(5):502-507. PubMed ID: 27322703
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
Forsythe K; Blacksburg S; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
[TBL] [Abstract][Full Text] [Related]
17. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.
Pan HY; Jiang J; Hoffman KE; Tang C; Choi SL; Nguyen QN; Frank SJ; Anscher MS; Shih YT; Smith BD
J Clin Oncol; 2018 Jun; 36(18):1823-1830. PubMed ID: 29561693
[TBL] [Abstract][Full Text] [Related]
18. Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques.
Dee EC; Muralidhar V; King MT; Martin NE; D'Amico AV; Mouw KW; Orio PF; Nguyen PL; Leeman JE
Radiother Oncol; 2021 Aug; 161():241-250. PubMed ID: 34171451
[TBL] [Abstract][Full Text] [Related]
19. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
20. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]